董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kim Kelderman | 男 | President, Chief Executive Officer and Director | 58 | 815.12万美元 | 37.84 | 2025-10-30 |
| Alpna Seth | 女 | Director | 62 | 28.54万美元 | 4.13 | 2025-10-30 |
| Judith Klimovsky | 女 | Director | 68 | 27.53万美元 | 0.73 | 2025-10-30 |
| Rupert Vessey | 男 | Director | 60 | 27.54万美元 | 3.92 | 2025-10-30 |
| Julie Bushman | 女 | Director | 64 | 29.29万美元 | 2.80 | 2025-10-30 |
| Amy E. Herr | -- | Director | 50 | 18.14万美元 | 0.13 | 2025-10-30 |
| Robert V. Baumgartner | 男 | Chair of the Board | 69 | 40.04万美元 | 10.84 | 2025-10-30 |
| John L. Higgins | 男 | Director | 55 | 30.04万美元 | 12.88 | 2025-10-30 |
| Joseph D. Keegan | 男 | Director | 71 | 27.54万美元 | 6.14 | 2025-10-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kim Kelderman | 男 | President, Chief Executive Officer and Director | 58 | 815.12万美元 | 37.84 | 2025-10-30 |
| James T. Hippel | 男 | Executive Vice President and Chief Financial Officer | 54 | 702.74万美元 | 58.88 | 2025-10-30 |
| William Geist | 男 | President, Protein Sciences | 55 | 313.93万美元 | 6.96 | 2025-10-30 |
| Shane Bohnen | 男 | Senior Vice President, General Counsel and Secretary | 50 | 198.07万美元 | 4.18 | 2025-10-30 |
| Matthew F. McManus | 男 | President, Diagnostics and Spatial Biology | 56 | 284.66万美元 | 1.40 | 2025-10-30 |
董事简历
中英对照 | 中文 | 英文- Kim Kelderman
-
Kim Kelderman于2018年4月30日加入Bio-Techne，担任诊断和基因组学总裁。在加入Bio-Techne之前，Kelderman先生受雇于Thermo Fisher Scientific，在那里他领导了三个规模和复杂性不断增加的不同业务。在过去三年中，Kelderman先生管理着遗传科学部门的平台和内容，负责仪器、软件、耗材和分析业务，以及应用生物系统和legacy Affymetrix等品牌。在加入Thermo Fisher之前，Kim曾担任Becton Dickinson的高级部门主管，负责管理 global Blood“Vacutainer”业务。
Kim Kelderman,was promoted to President and Chief Executive Officer of the Company on February 1, 2024 and has been an executive officer of the Company since joining the Company in 2018. Prior to joining the Company, he served as an executive at Thermo Fisher Scientific and as a Senior Segment Leader at Becton Dickinson. - Kim Kelderman于2018年4月30日加入Bio-Techne，担任诊断和基因组学总裁。在加入Bio-Techne之前，Kelderman先生受雇于Thermo Fisher Scientific，在那里他领导了三个规模和复杂性不断增加的不同业务。在过去三年中，Kelderman先生管理着遗传科学部门的平台和内容，负责仪器、软件、耗材和分析业务，以及应用生物系统和legacy Affymetrix等品牌。在加入Thermo Fisher之前，Kim曾担任Becton Dickinson的高级部门主管，负责管理 global Blood“Vacutainer”业务。
- Kim Kelderman,was promoted to President and Chief Executive Officer of the Company on February 1, 2024 and has been an executive officer of the Company since joining the Company in 2018. Prior to joining the Company, he served as an executive at Thermo Fisher Scientific and as a Senior Segment Leader at Becton Dickinson.
- Alpna Seth
-
Alpna Seth于2019年8月被任命为Nura Bio Inc.的总裁兼首席执行官。Seth博士也是SeaGen，Inc.的董事会成员。2019年1月之前，她一直担任Vir生物技术公司的首席运营官。2017年7月加入Vir之前，Seth博士在Biogen Inc.工作了近二十年，最近一次担任高级副总裁兼总部位于瑞士的Biosimirs业务全球总监。1998年至2014年期间，Seth博士在研发和商业领域担任了一系列高级领导职务，主要总部设在美国剑桥的Biogen全球总部。这包括领导几个主要的药物开发项目和产品发布，以及战略、业务发展和长期规划计划。在另一项国际综合管理任务中，她担任了一家印度分支机构的创始常务董事，也是Biogen亚太区领导团队的成员。她拥有博士学位。来自麻州大学医学院的生物化学和分子生物学，并在哈佛大学进行了博士后研究，在免疫学和结构生物学方面，均作为霍华德休斯医学研究所研究员。
Alpna Seth,retired as President and Chief Executive Officer of Nura Bio Inc., a biopharmaceutical company focused on the discovery of novel neuroprotective drugs, in 2022 after serving in that role for three years. From July 2017 through January 2019, she was Chief Operating Officer of Vir Biotechnology, Inc., an immunology company. Prior to joining Vir, Dr. Seth was at Biogen Inc. for nearly two decades, most recently as Senior Vice President and global head of the Biosimilars business, headquartered in Switzerland. For the period from 1998 through 2014, Dr. Seth held a range of senior leadership roles across R&D and commercial arenas. In this capacity, she led several major drug development programs and product launches, along with strategic, business development, and long-range planning initiatives. In another international general management assignment, Dr. Seth served as the founding Managing Director of an India affiliate and was a member of Biogen's Asia Pacific Leadership Team.Ph.D. in Biochemistry and Molecular Biology, University of Massachusetts Medical School. Conducted post- doctoral research at Harvard University in Immunology and Structural Biology, both as a Howard Hughes Medical Institute Fellow. Dr. Seth is a graduate of Harvard Business School's Advanced Management Program. - Alpna Seth于2019年8月被任命为Nura Bio Inc.的总裁兼首席执行官。Seth博士也是SeaGen，Inc.的董事会成员。2019年1月之前，她一直担任Vir生物技术公司的首席运营官。2017年7月加入Vir之前，Seth博士在Biogen Inc.工作了近二十年，最近一次担任高级副总裁兼总部位于瑞士的Biosimirs业务全球总监。1998年至2014年期间，Seth博士在研发和商业领域担任了一系列高级领导职务，主要总部设在美国剑桥的Biogen全球总部。这包括领导几个主要的药物开发项目和产品发布，以及战略、业务发展和长期规划计划。在另一项国际综合管理任务中，她担任了一家印度分支机构的创始常务董事，也是Biogen亚太区领导团队的成员。她拥有博士学位。来自麻州大学医学院的生物化学和分子生物学，并在哈佛大学进行了博士后研究，在免疫学和结构生物学方面，均作为霍华德休斯医学研究所研究员。
- Alpna Seth,retired as President and Chief Executive Officer of Nura Bio Inc., a biopharmaceutical company focused on the discovery of novel neuroprotective drugs, in 2022 after serving in that role for three years. From July 2017 through January 2019, she was Chief Operating Officer of Vir Biotechnology, Inc., an immunology company. Prior to joining Vir, Dr. Seth was at Biogen Inc. for nearly two decades, most recently as Senior Vice President and global head of the Biosimilars business, headquartered in Switzerland. For the period from 1998 through 2014, Dr. Seth held a range of senior leadership roles across R&D and commercial arenas. In this capacity, she led several major drug development programs and product launches, along with strategic, business development, and long-range planning initiatives. In another international general management assignment, Dr. Seth served as the founding Managing Director of an India affiliate and was a member of Biogen's Asia Pacific Leadership Team.Ph.D. in Biochemistry and Molecular Biology, University of Massachusetts Medical School. Conducted post- doctoral research at Harvard University in Immunology and Structural Biology, both as a Howard Hughes Medical Institute Fellow. Dr. Seth is a graduate of Harvard Business School's Advanced Management Program.
- Judith Klimovsky
-
Judith Klimovsky医学博士他目前是丹麦生物技术公司Genmab A/S的执行副总裁兼首席开发官。在加入Genmab A/S之前，Klimovsky博士在Novartis Oncology （Novartis AG的一个部门）和bristol - myers Squibb Company担任各种高级全球临床和研究职位。Klimovsky博士拥有布宜诺斯艾利斯大学的医学博士学位。
Judith Klimovsky,is the Executive Vice President and Chief Development Officer at Genmab, an international biotechnology company that specializes in the creation and development of antibody therapeutics. At Genmab, Dr. Klimovsky has built an R&D team from under 20 to over 500, commercializing multiple products through development and regulatory approval. Before joining Genmab in 2017, Dr. Klimovsky held various senior global clinical and research positions at Novartis Oncology, a division of Novartis AG, including SVP & Global Head, Oncology Clinical Development. Dr. Klimovsky also served as Regional Medical Director, Latin America for Merck & Co. and held several research and development roles of increasing responsibility at Bristol-Myers Squibb Company.Dr. Klimovsky received her M.D. from the Universidad de Buenos Aires. - Judith Klimovsky医学博士他目前是丹麦生物技术公司Genmab A/S的执行副总裁兼首席开发官。在加入Genmab A/S之前，Klimovsky博士在Novartis Oncology （Novartis AG的一个部门）和bristol - myers Squibb Company担任各种高级全球临床和研究职位。Klimovsky博士拥有布宜诺斯艾利斯大学的医学博士学位。
- Judith Klimovsky,is the Executive Vice President and Chief Development Officer at Genmab, an international biotechnology company that specializes in the creation and development of antibody therapeutics. At Genmab, Dr. Klimovsky has built an R&D team from under 20 to over 500, commercializing multiple products through development and regulatory approval. Before joining Genmab in 2017, Dr. Klimovsky held various senior global clinical and research positions at Novartis Oncology, a division of Novartis AG, including SVP & Global Head, Oncology Clinical Development. Dr. Klimovsky also served as Regional Medical Director, Latin America for Merck & Co. and held several research and development roles of increasing responsibility at Bristol-Myers Squibb Company.Dr. Klimovsky received her M.D. from the Universidad de Buenos Aires.
- Rupert Vessey
-
Rupert Vessey目前是Celgene全球研究与早期开发总裁，并有望在对Celgene的最终收购完成后在百时美施贵宝（Bristol-Myers Squibb）担任该职位。 在Celgene任职期间，Vessey博士从2017年4月开始担任Juno Therapeutics董事会成员，直到2018年3月被Celgene收购为止。在加入Celgene之前，Vessey博士在默克公司担任过各种研发高级管理职务。 Vessey博士拥有牛津大学生理科学硕士学位和临床医学BMCh学位，在那里他在牛津分子医学研究所完成了他的博士学位，并在英国的多家医院进行了额外的临床培训。 他是英国伦敦皇家内科医学院的成员。 他还是私人疗法公司Pharmakea的董事会成员。
Rupert Vessey,joined Flagship Pioneering (a life sciences venture capital company) as Executive Partner and Chief Scientist in July 2023 after retiring from Bristol-Myers Squibb, where he had served as the President of Research and Early Development since 2019. Prior to joining Bristol-Myers Squibb, he was President of Global Research and Early Development at Celgene from 2015 to 2019. During that time, Dr. Vessey also served on the board of Juno Therapeutics for one year. Before joining Celgene, Dr. Vessey held various research and development senior management positions during his 10-year tenure at Merck.Dr. Vessey is a member of the Royal College of Physicians of London UK. Dr. Vessey serves on the Board of Directors for Generate: Biomedicines.MA in physiological sciences and BM BCh in clinical medicine from Oxford University. DPhil at the Institute for Molecular Medicine, Oxford. - Rupert Vessey目前是Celgene全球研究与早期开发总裁，并有望在对Celgene的最终收购完成后在百时美施贵宝（Bristol-Myers Squibb）担任该职位。 在Celgene任职期间，Vessey博士从2017年4月开始担任Juno Therapeutics董事会成员，直到2018年3月被Celgene收购为止。在加入Celgene之前，Vessey博士在默克公司担任过各种研发高级管理职务。 Vessey博士拥有牛津大学生理科学硕士学位和临床医学BMCh学位，在那里他在牛津分子医学研究所完成了他的博士学位，并在英国的多家医院进行了额外的临床培训。 他是英国伦敦皇家内科医学院的成员。 他还是私人疗法公司Pharmakea的董事会成员。
- Rupert Vessey,joined Flagship Pioneering (a life sciences venture capital company) as Executive Partner and Chief Scientist in July 2023 after retiring from Bristol-Myers Squibb, where he had served as the President of Research and Early Development since 2019. Prior to joining Bristol-Myers Squibb, he was President of Global Research and Early Development at Celgene from 2015 to 2019. During that time, Dr. Vessey also served on the board of Juno Therapeutics for one year. Before joining Celgene, Dr. Vessey held various research and development senior management positions during his 10-year tenure at Merck.Dr. Vessey is a member of the Royal College of Physicians of London UK. Dr. Vessey serves on the Board of Directors for Generate: Biomedicines.MA in physiological sciences and BM BCh in clinical medicine from Oxford University. DPhil at the Institute for Molecular Medicine, Oxford.
- Julie Bushman
-
Julie Bushman于2020年2月从3M公司退休，最近担任国际运营执行副总裁。她于1983年加入3M公司，之前曾在3M公司担任各种行政职务，包括担任业务转型和信息技术高级副总裁；负责安全、安保和保护服务的执行副总裁；安全和图形执行副总裁；事业部职业健康与环境安全处副处长；和首席信息官。Bushman女士还担任汽车座椅公司Adient plc和能源制造和物流公司Phillips 66的独立董事。
Julie Bushman,retired in 2020 from 3M Corporation, where she most recently served as Executive Vice President of International Operations. She joined 3M in 1983, and served in various executive positions, including Senior Vice President of Business Transformation and Information Technology; Executive Vice President of Safety, Security and Protection Services; Executive Vice President of Safety and Graphics; Division Vice President of the Occupational Health and Environmental Safety Division; and Chief Information Officer.Bachelor of Science, University of Wisconsin-River Falls. - Julie Bushman于2020年2月从3M公司退休，最近担任国际运营执行副总裁。她于1983年加入3M公司，之前曾在3M公司担任各种行政职务，包括担任业务转型和信息技术高级副总裁；负责安全、安保和保护服务的执行副总裁；安全和图形执行副总裁；事业部职业健康与环境安全处副处长；和首席信息官。Bushman女士还担任汽车座椅公司Adient plc和能源制造和物流公司Phillips 66的独立董事。
- Julie Bushman,retired in 2020 from 3M Corporation, where she most recently served as Executive Vice President of International Operations. She joined 3M in 1983, and served in various executive positions, including Senior Vice President of Business Transformation and Information Technology; Executive Vice President of Safety, Security and Protection Services; Executive Vice President of Safety and Graphics; Division Vice President of the Occupational Health and Environmental Safety Division; and Chief Information Officer.Bachelor of Science, University of Wisconsin-River Falls.
- Amy E. Herr
-
Amy E. Herr目前是加州大学伯克利分校生物工程学的校长教授，也是Chan Zuckerberg Biohub Network的副总裁，该网络是一组非营利研究机构，专注于了解疾病的潜在机制，并开发新技术，这些技术将导致可操作的诊断和有效的疗法。Herr博士拥有斯坦福大学理学硕士学位和哲学博士学位。
Amy E. Herr,is currently a Chancellor's Professor of Bioengineering at the University of California, Berkeley and the Vice President of Chan Zuckerberg Biohub Network, a group of nonprofit research institutes that focuses on understanding underlying mechanisms of disease and developing new technologies that will lead to actionable diagnostics and effective therapies. Dr. Herr holds a Master of Science degree and a Doctor of Philosophy degree from Stanford University. - Amy E. Herr目前是加州大学伯克利分校生物工程学的校长教授，也是Chan Zuckerberg Biohub Network的副总裁，该网络是一组非营利研究机构，专注于了解疾病的潜在机制，并开发新技术，这些技术将导致可操作的诊断和有效的疗法。Herr博士拥有斯坦福大学理学硕士学位和哲学博士学位。
- Amy E. Herr,is currently a Chancellor's Professor of Bioengineering at the University of California, Berkeley and the Vice President of Chan Zuckerberg Biohub Network, a group of nonprofit research institutes that focuses on understanding underlying mechanisms of disease and developing new technologies that will lead to actionable diagnostics and effective therapies. Dr. Herr holds a Master of Science degree and a Doctor of Philosophy degree from Stanford University.
- Robert V. Baumgartner
-
Robert V. Baumgartner，2003年起，他担任公司董事会成员，2012年起，担任主席。他在圣母大学（University of Notre Dame）获得工商管理学士学位。2001年起，他担任Center for Diagnostic Imaging, Inc.的执行主席、首席执行官和董事，该公司是诊断成像中心运营公司。2001年之前，他担任多个执行职位，包括American Coating International的首席执行官和董事、First Solar的总裁和首席执行官和Apogee Glass Group的总裁。他在国际会计师事务所毕马威（KPMG LLC）开始职业生涯。他目前担任Carestream Health, Inc.的董事会成员。
Robert V. Baumgartner,From 2001 until 2019, Mr. Baumgartner served as Executive Chairman, Director of the Center for Diagnostic Imaging, Inc., an operator of diagnostic imaging centers. Prior to August 2015, Mr. Baumgartner also served as Chief Executive Officer of that company. Before joining the Center for Diagnostic Imaging, he held numerous executive positions, including Chief Executive Officer and Director of American Coating International, President and Chief Executive Officer of First Solar, and President of the Apogee Glass Group. Mr. Baumgartner began his professional career at KPMG LLP, an international accounting firm, and is a CPA.Bachelor's degree in business administration, University of Notre Dame. - Robert V. Baumgartner，2003年起，他担任公司董事会成员，2012年起，担任主席。他在圣母大学（University of Notre Dame）获得工商管理学士学位。2001年起，他担任Center for Diagnostic Imaging, Inc.的执行主席、首席执行官和董事，该公司是诊断成像中心运营公司。2001年之前，他担任多个执行职位，包括American Coating International的首席执行官和董事、First Solar的总裁和首席执行官和Apogee Glass Group的总裁。他在国际会计师事务所毕马威（KPMG LLC）开始职业生涯。他目前担任Carestream Health, Inc.的董事会成员。
- Robert V. Baumgartner,From 2001 until 2019, Mr. Baumgartner served as Executive Chairman, Director of the Center for Diagnostic Imaging, Inc., an operator of diagnostic imaging centers. Prior to August 2015, Mr. Baumgartner also served as Chief Executive Officer of that company. Before joining the Center for Diagnostic Imaging, he held numerous executive positions, including Chief Executive Officer and Director of American Coating International, President and Chief Executive Officer of First Solar, and President of the Apogee Glass Group. Mr. Baumgartner began his professional career at KPMG LLP, an international accounting firm, and is a CPA.Bachelor's degree in business administration, University of Notre Dame.
- John L. Higgins
-
John L. Higgins，Ligand Pharmaceuticals Incorporated总裁、首席执行官和董事。加入 Ligand之前，他曾担任 Connetics Corporation（一家特殊制药公司，2006年被Stiefel Laboratories收购）首席财务官、金融、行政和企业发展执行副总裁。加入 Connetics之前，他是BioCryst Pharmaceuticals执行管理小组成员。在此之前，他是Dillon, Read & Co. Inc.（一家投资银行公司）健康医疗银行小组成员。现在他是Techne Corporation、CoMentis and Blue Zones董事，并且担任Techne审计委员会主席和CoMentis审计委员会主席。他之前是BioCryst的董事。他也是Techne薪酬委员会成员和 CoMentis薪酬委员会成员。他以优异成绩毕业于科尔盖特大学，持有经济学文学士学位。
John L. Higgins,retired as President and Chief Executive Officer and a member of the Board of Directors of Ligand Pharmaceuticals, Inc. in December 2022. From 1997 until he joined Ligand in 2007, Mr. Higgins was with Connetics Corporation, a specialty pharmaceutical company, as its Chief Financial Officer, and also served as Executive Vice President, Finance and Administration and Corporate Development from 2002 until 2006. Mr. Higgins previously was a member of the executive management team and a director at BioCryst Pharmaceuticals, Inc., a biopharmaceutical company. Earlier in his career, Mr. Higgins was a member of the healthcare banking team of Dillon, Read & Co. Inc., an investment banking firm. Mr. Higgins has served as a director of several public and private companies.Bachelor's degree in economics, Magna Cum Laude, Colgate University. - John L. Higgins，Ligand Pharmaceuticals Incorporated总裁、首席执行官和董事。加入 Ligand之前，他曾担任 Connetics Corporation（一家特殊制药公司，2006年被Stiefel Laboratories收购）首席财务官、金融、行政和企业发展执行副总裁。加入 Connetics之前，他是BioCryst Pharmaceuticals执行管理小组成员。在此之前，他是Dillon, Read & Co. Inc.（一家投资银行公司）健康医疗银行小组成员。现在他是Techne Corporation、CoMentis and Blue Zones董事，并且担任Techne审计委员会主席和CoMentis审计委员会主席。他之前是BioCryst的董事。他也是Techne薪酬委员会成员和 CoMentis薪酬委员会成员。他以优异成绩毕业于科尔盖特大学，持有经济学文学士学位。
- John L. Higgins,retired as President and Chief Executive Officer and a member of the Board of Directors of Ligand Pharmaceuticals, Inc. in December 2022. From 1997 until he joined Ligand in 2007, Mr. Higgins was with Connetics Corporation, a specialty pharmaceutical company, as its Chief Financial Officer, and also served as Executive Vice President, Finance and Administration and Corporate Development from 2002 until 2006. Mr. Higgins previously was a member of the executive management team and a director at BioCryst Pharmaceuticals, Inc., a biopharmaceutical company. Earlier in his career, Mr. Higgins was a member of the healthcare banking team of Dillon, Read & Co. Inc., an investment banking firm. Mr. Higgins has served as a director of several public and private companies.Bachelor's degree in economics, Magna Cum Laude, Colgate University.
- Joseph D. Keegan
-
Joseph D. Keegan 目前担任 Interpace Diagnostics 以及多家私营生命科学公司的董事和顾问。 从 2007 年到 2012 年将其出售给 Pall Corporation，Keegan 博士担任 ForteBio, Inc. 的总裁兼首席执行官。Keegan 博士从 Molecular Devices Corporation 加入 ForteBio，并于 1998 年至 2007 年担任该公司的总裁兼首席执行官。 在加入 Molecular Devices 之后，Keegan 博士曾在 Becton Dickinson、Leica, Inc. 和 GE Medical Systems 担任领导职务。 他还曾在众多生命科学工具公司的上市和私营公司董事会任职，包括流体分析主席和 Halo Labs 执行主席。 Keegan 博士拥有博士学位。 斯坦福大学物理化学博士。
Joseph D. Keegan,serves as a director and advisor for Interpace Diagnostics. From 2007 until 2012, Dr. Keegan served as President and Chief Executive Officer of ForteBio, Inc., a life science tools company. He joined ForteBio after serving as President and Chief Executive Officer of Molecular Devices Corporation from 1998 to 2007. Earlier in his career, Dr. Keegan held leadership positions at Becton Dickinson, Leica, Inc., and GE Medical Systems.Dr. Keegan has served on numerous public and private company boards of life science tools companies, including as Executive Chair of both Halo Labs and Carterra, as well as Non-Executive Chairman for Arrayjet and Director for Nuclera and Biolog.Ph.D. in Physical Chemistry, Stanford University. - Joseph D. Keegan 目前担任 Interpace Diagnostics 以及多家私营生命科学公司的董事和顾问。 从 2007 年到 2012 年将其出售给 Pall Corporation，Keegan 博士担任 ForteBio, Inc. 的总裁兼首席执行官。Keegan 博士从 Molecular Devices Corporation 加入 ForteBio，并于 1998 年至 2007 年担任该公司的总裁兼首席执行官。 在加入 Molecular Devices 之后，Keegan 博士曾在 Becton Dickinson、Leica, Inc. 和 GE Medical Systems 担任领导职务。 他还曾在众多生命科学工具公司的上市和私营公司董事会任职，包括流体分析主席和 Halo Labs 执行主席。 Keegan 博士拥有博士学位。 斯坦福大学物理化学博士。
- Joseph D. Keegan,serves as a director and advisor for Interpace Diagnostics. From 2007 until 2012, Dr. Keegan served as President and Chief Executive Officer of ForteBio, Inc., a life science tools company. He joined ForteBio after serving as President and Chief Executive Officer of Molecular Devices Corporation from 1998 to 2007. Earlier in his career, Dr. Keegan held leadership positions at Becton Dickinson, Leica, Inc., and GE Medical Systems.Dr. Keegan has served on numerous public and private company boards of life science tools companies, including as Executive Chair of both Halo Labs and Carterra, as well as Non-Executive Chairman for Arrayjet and Director for Nuclera and Biolog.Ph.D. in Physical Chemistry, Stanford University.
高管简历
中英对照 | 中文 | 英文- Kim Kelderman
Kim Kelderman于2018年4月30日加入Bio-Techne，担任诊断和基因组学总裁。在加入Bio-Techne之前，Kelderman先生受雇于Thermo Fisher Scientific，在那里他领导了三个规模和复杂性不断增加的不同业务。在过去三年中，Kelderman先生管理着遗传科学部门的平台和内容，负责仪器、软件、耗材和分析业务，以及应用生物系统和legacy Affymetrix等品牌。在加入Thermo Fisher之前，Kim曾担任Becton Dickinson的高级部门主管，负责管理 global Blood“Vacutainer”业务。
Kim Kelderman,was promoted to President and Chief Executive Officer of the Company on February 1, 2024 and has been an executive officer of the Company since joining the Company in 2018. Prior to joining the Company, he served as an executive at Thermo Fisher Scientific and as a Senior Segment Leader at Becton Dickinson.- Kim Kelderman于2018年4月30日加入Bio-Techne，担任诊断和基因组学总裁。在加入Bio-Techne之前，Kelderman先生受雇于Thermo Fisher Scientific，在那里他领导了三个规模和复杂性不断增加的不同业务。在过去三年中，Kelderman先生管理着遗传科学部门的平台和内容，负责仪器、软件、耗材和分析业务，以及应用生物系统和legacy Affymetrix等品牌。在加入Thermo Fisher之前，Kim曾担任Becton Dickinson的高级部门主管，负责管理 global Blood“Vacutainer”业务。
- Kim Kelderman,was promoted to President and Chief Executive Officer of the Company on February 1, 2024 and has been an executive officer of the Company since joining the Company in 2018. Prior to joining the Company, he served as an executive at Thermo Fisher Scientific and as a Senior Segment Leader at Becton Dickinson.
- James T. Hippel
James T. Hippel从2014年4月1日开始一直担任该公司的首席财务官。加入该公司前，Hippel先生担任Mirion Technologies, Inc.的高级副总裁兼首席财务官，这是一家收入达3亿美元的全球性公司，其提供辐射检测和识别产品。加入Mirion前，Hippel先生担任赛默飞世尔科技有限公司（Thermo Fisher Scientific, Inc.）的财务部副总裁，领导了其质谱分析法与色谱法部门和其实验室消耗品部门的财务运营。此外，Hippel先生的工作经验包括担任霍尼韦尔国际公司（Honeywell International）航空航天部门的职责递增的财务领导职位达9年。Hippel先生在毕马威会计事务所（KPMG LLP）开启其职业生涯，并是一位非执业的注册会计师。
James T. Hippel,has been Chief Financial Officer of the Company since April 1, 2014. Prior to joining the Company, Mr. Hippel served as Senior Vice President and Chief Financial Officer for Mirion Technologies, Inc and as Vice President, Finance at Thermo Fisher Scientific, and in financial roles at Honeywell International. Mr. Hippel started his career with KPMG LLP.- James T. Hippel从2014年4月1日开始一直担任该公司的首席财务官。加入该公司前，Hippel先生担任Mirion Technologies, Inc.的高级副总裁兼首席财务官，这是一家收入达3亿美元的全球性公司，其提供辐射检测和识别产品。加入Mirion前，Hippel先生担任赛默飞世尔科技有限公司（Thermo Fisher Scientific, Inc.）的财务部副总裁，领导了其质谱分析法与色谱法部门和其实验室消耗品部门的财务运营。此外，Hippel先生的工作经验包括担任霍尼韦尔国际公司（Honeywell International）航空航天部门的职责递增的财务领导职位达9年。Hippel先生在毕马威会计事务所（KPMG LLP）开启其职业生涯，并是一位非执业的注册会计师。
- James T. Hippel,has been Chief Financial Officer of the Company since April 1, 2014. Prior to joining the Company, Mr. Hippel served as Senior Vice President and Chief Financial Officer for Mirion Technologies, Inc and as Vice President, Finance at Thermo Fisher Scientific, and in financial roles at Honeywell International. Mr. Hippel started his career with KPMG LLP.
- William Geist
William Geist 自 2022 年 1 月 3 日起担任Protein Sciences segment总裁。在加入 Bio-Techne 之前，Geist 先生最近担任 Quanterix 的首席运营官，此前曾在 Thermo Fisher Scientific 和 Quanta Biosciences, a QIAGEN担任高级管理职务。
William Geist,has been President of the Protein Sciences segment since January 3, 2022. Prior to Bio-Techne, Mr. Geist most recently served as Chief Operating Officer for Quanterix, and before that in senior management roles at Thermo Fisher Scientific and QuantaBiosciences, a QIAGEN company.- William Geist 自 2022 年 1 月 3 日起担任Protein Sciences segment总裁。在加入 Bio-Techne 之前，Geist 先生最近担任 Quanterix 的首席运营官，此前曾在 Thermo Fisher Scientific 和 Quanta Biosciences, a QIAGEN担任高级管理职务。
- William Geist,has been President of the Protein Sciences segment since January 3, 2022. Prior to Bio-Techne, Mr. Geist most recently served as Chief Operating Officer for Quanterix, and before that in senior management roles at Thermo Fisher Scientific and QuantaBiosciences, a QIAGEN company.
- Shane Bohnen
Shane Bohnen，于2023年3月3日晋升为总法律顾问兼公司秘书，自2019年7月起担任公司法律团队的律师。加入Bio-Techne之前，他在私人执业中担任生命科学诉讼律师10年，随后担任公司内部法律顾问7年，覆盖全球责任广泛。
Shane Bohnen,was promoted to General Counsel and Corporate Secretary on March 3, 2023, and has been an attorney on the Company's legal team since July 2019. Prior to joining Bio-Techne, Mr. Bohnen spent 10 years in private practice as a life sciences litigator, followed by seven years as in-house corporate counsel with an expansive breadth of responsibility and global scope.- Shane Bohnen，于2023年3月3日晋升为总法律顾问兼公司秘书，自2019年7月起担任公司法律团队的律师。加入Bio-Techne之前，他在私人执业中担任生命科学诉讼律师10年，随后担任公司内部法律顾问7年，覆盖全球责任广泛。
- Shane Bohnen,was promoted to General Counsel and Corporate Secretary on March 3, 2023, and has been an attorney on the Company's legal team since July 2019. Prior to joining Bio-Techne, Mr. Bohnen spent 10 years in private practice as a life sciences litigator, followed by seven years as in-house corporate counsel with an expansive breadth of responsibility and global scope.
- Matthew F. McManus
Matthew F. McManus，拥有20多年的资深生命科学领导者经验，最近担任Azenta的执行副总裁兼首席运营官，负责生命科学产品、服务和业务的所有商业运营。此前，McManus博士在收购Asuragen后担任Bio-Techne分子诊断部门的高级副总裁兼总经理，McManus博士在Asuragen担任总裁兼首席执行官。McManus博士目前担任ANSA（一家将基因合成和细胞与基因治疗市场的破坏性能力商业化的公司）的董事会主席。他持有宾夕法尼亚大学医学院的医学博士和博士学位，波士顿学院的工商管理硕士学位，以及圣十字学院的经济学学士学位。
Matthew F. McManus,joined Bio-Techne on January 8, 2024 as President, Diagnostics and Spatial Biology. Prior to Bio-Techne, Mr. McManus most recently served as Chief Operating Officer for Azenta Life Sciences and served as Chief Executive Officer of Asuragen prior to the Bio-Techne acquisition.- Matthew F. McManus，拥有20多年的资深生命科学领导者经验，最近担任Azenta的执行副总裁兼首席运营官，负责生命科学产品、服务和业务的所有商业运营。此前，McManus博士在收购Asuragen后担任Bio-Techne分子诊断部门的高级副总裁兼总经理，McManus博士在Asuragen担任总裁兼首席执行官。McManus博士目前担任ANSA（一家将基因合成和细胞与基因治疗市场的破坏性能力商业化的公司）的董事会主席。他持有宾夕法尼亚大学医学院的医学博士和博士学位，波士顿学院的工商管理硕士学位，以及圣十字学院的经济学学士学位。
- Matthew F. McManus,joined Bio-Techne on January 8, 2024 as President, Diagnostics and Spatial Biology. Prior to Bio-Techne, Mr. McManus most recently served as Chief Operating Officer for Azenta Life Sciences and served as Chief Executive Officer of Asuragen prior to the Bio-Techne acquisition.